Adjuvant Therapies And Markers Of Post-surgical Minimal Residual Disease Ii: Adjuvant Therapies Of The Various Primary Tumors (recent Results In Cancer Research)

Front Matter....Pages I-XI Wilms’ Tumor: Assessment and Treatment of Residual Disease....Pages 1-4 Adjuvant Therapy in the Management of Osteosarcoma: Need for Critical Reassessment....Pages 5-15 Adjuvant Therapy of Operable Primary Osteosarcoma-Cancer and Leukemia Group B Experience....Pages 16-24 Adriamycin in the Adjuvant Treatment of Operable Osteosarcoma....Pages 25-27 Randomized Trial of Adjuvant Chemotherapy in Osteogenic Osteosarcoma: Comparison of Altering Sequential Administrations of High Doses of Adriamycin, Methotrexate, and Cyclophosphamide with a 6-Month Administration of High-Dose Adriamycin Followed by a Low-Dose Semicontinuous Chemotherapy....Pages 28-32 Biochemistry of the Citrovorum Factor Rescue Effect in Normal Bone Marrow Cells After High-Dose Methotrexate Treatment: Implications for Therapy....Pages 33-39 Adjuvant Interferon Treatment of Human Osteosarcoma....Pages 40-44 Current Results With a Combined Treatment Approach to Localized Ewing’s Sarcoma....Pages 45-51 EORTC/GTO Adjuvant Chemotherapy Program for Primary Ewing’s Sarcoma: Results at 5 Years....Pages 52-59 Adjuvant Treatment of Soft Tissue Sarcoma in Children and Adults....Pages 60-74 Place and Role of Radiotherapy After Surgery for Breast Cancer....Pages 75-79 Combined Modality Management of Operable Breast Cancer....Pages 80-97 Treatment of Early Breast Cancer With Adriamycin-Cyclophosphamide With or Without Radiation Therapy: Initial Results of a Brief and Effective Adjuvant Program....Pages 98-104 Results of a Randomized Trial of Prophylactic Chemotherapy in T 3 -T 4 Breast Cancer Patients Previously Treated by Radiotherapy....Pages 105-108 Four Drug Combination Cytotoxic Chemotherapy Following Surgery for Breast Cancer....Pages 109-112 Pilot Study on Adjuvant Chemotherapy and Hormonal Therapy for Irradiated Inoperable Breast Cancer....Pages 113-117 Ovarian Irradiation and Prednisone Following Surgery and Radiotherapy for Carcinoma of the Breast....Pages 118-122 Adjuvant Therapy of Stage II, III Breast Cancer....Pages 123-128 Randomized Trial With Poly A-Poly U as Adjuvant Therapy Complementing Surgery in Patients With Breast Cancer: In Vitro Study of Cellular Immunity....Pages 129-138 Levamisole: As Adjuvant to Cyclic Chemotherapy in Breast Cancer....Pages 139-145 Laparoscopy and Peritoneal Cytology as Markers in the Follow-Up of Ovarian Epithelial Tumors....Pages 146-151 Radiotherapy in Ovarian Cancer for Post-Surgical Minimal Residual Disease....Pages 152-156 Chemotherapeutic Sensitivity of Minimal Residual Disease Following Surgical Excision of Ovarian Carcinoma....Pages 157-159 Chemoimmunotherapy for Advanced Ovarian Carcinoma With Adriamycin-Cyclophosphamide ± BCG: Early Report of a Southwest Oncology Group Study....Pages 160-165 Active Specific Immunotherapy in Ovarian Cancer....Pages 166-173 Clinical Studies on PSK: Combination Therapy of PSK With Radiation in Cancer of the Uterine Cervix....Pages 174-177 Irradiation as Adjuvant Therapy in the Management of Testicular Tumors....Pages 178-185 Adjuvant Chemotherapy in Embryonal Carcinoma of the Testis....Pages 186-191 Adjuvant Chemotherapy of Testicular Carcinoma: Need for Evaluation of Curative Strategies....Pages 192-200 Results of Cytostatic Therapy of Metastasizing Testicular Tumors....Pages 201-207 Treatment of Patients With Gastric Cancer by Surgery, Radiotherapy, and Chemotherapy: Preliminary Results of an EORTC Randomized Study....Pages 208-211 Chemotherapy for Known Residual Disease After Resection of Gastric and Colorectal Cancer....Pages 212-216 Adjuvant Treatment With Razoxane (ICRF 159) Following Resection of Cancer of the Stomach....Pages 217-221 Adjuvant Chemotherapy in Large-Bowel Cancer: Demonstration of Effectiveness of Single Agent Chemotherapy in a Prospectively Controlled, Randomized Trial....Pages 222-230 Ongoing Trials in the Surgical Adjuvant Management of Colorectal Cancer....Pages 231-235 Clinical Studies on PSK: Combination Therapy of PSK With Surgery and Chemotherapy....Pages 236-240 Role of Radiotherapy as an Adjuvant Therapy in Operable Bronchus Carcinoma....Pages 241-241 Influence of Postoperative Radiotherapy on Local Recurrence and Survival of Bronchial Epidermoid Carcinoma With Regard to Nodal Status: Preliminary Results of the EORTC Protocol 08741....Pages 242-243 Preliminary Trends of the EORTC Study Comparing Postoperative Chemotherapy, Immunotherapy, Chemoimmunotherapy or Abstention in Squamous Cell Bronchial Carcinoma....Pages 244-245 Adjuvant Chemotherapy of Post-Surgical Minimal Residual Bronchial Carcinomas....Pages 246-259 Attempt at Immunotherapy With Living BCG in Patients With Bronchus Carcinoma....Pages 260-267 Adjuvant Therapy With Levamisole in Resectable Lung Cancer....Pages 268-277 Specific Active Immunochemotherapy in Lung Cancer: A Survival Study....Pages 278-285 Patterns of Recurrence After Regional BCG Immunotherapy of Bronchial Cancer....Pages 286-291 Intrapleural BCG in Operable Lung Cancer....Pages 292-296 Adjuvant Chemoimmunotherapy of Head and Neck Cancer....Pages 297-308 Adjuvant Treatment of Tongue and Floor of the Mouth Cancers....Pages 309-317 First Results of a Randomized Trial on Immunotherapy of Head and Neck Tumors....Pages 318-323 Adjuvant Trial of Levamisole in Patients With Squamous Cancer of the Head and Neck: A Preliminary Report....Pages 324-333 Adjuvant Chemotherapy Following Radical Radiotherapy in T3 Bladder Carcinoma....Pages 334-337 Adjuvant Therapy of T1 Bladder Carcinoma: Preliminary Results of an EORTC Randomized Study....Pages 338-345 Adjuvant Chemotherapy or Chemoimmunotherapy in the Management of Primary Malignant Melanoma of Level III, IV, or V....Pages 346-358 Immunotherapy for Recurrent Malignant Melanoma: Efficacy of BCG in Prolonging the Postoperative Disease-Free Interval and Survival....Pages 359-362 Results of a Nonrandomized Trial in Malignant Melanoma Patients (Clark’s Stages III–V) Treated by Post-Surgical Chemoimmunotherapy....Pages 363-366 Value of Adjuvant Therapy With Bacille Calmette Guerin (BCG) or Dimethl Triazeno Imidazole Carboximide (DTIC) in the Control of Minimal Residual Disease in Stage II Melanoma....Pages 367-374 Controlled Study for Prolonged Chemotherapy, Immunotherapy, and Chemotherapy Plus Immunotherapy as an Adjuvant to Surgery in Malignant Melanoma (Trial 6): Preliminary Report....Pages 375-379 Adjuvant Therapy in Malignant Melanoma: A Trial of Immunotherapy, Chemotherapy, and Combined Treatment....Pages 380-386 Malignant Melanoma (Stage 1): A Clinical Trial of Adjuvant BCG Immunotherapy....Pages 387-392 Adjuvant Chemotherapy With Nitrosourea Compounds Following Surgery Plus Radiotherapy in Glioblastoma Multiforme....Pages 393-398 Treatment of Adult Malignant Gliomas....Pages 399-407 Adjuvant Chemotherapy in Malignant Brain Gliomas....Pages 408-411 Adjuvant Therapy for Residual Disease in Children With Medulloblastoma....Pages 412-422 Radiochemotherapy of Postoperative Minimal Residual Disease in Neuroblastoma....Pages 423-430 Adjuvant Systemic Therapy of Cancer: Rationale for Future Trials....Pages 431-438 Some New Chemotherapeutic Agents and Combinations Possibly Available for New Adjuvant Therapies of Minimal Disease....Pages 439-448 Third Generation of Systemic Adjuvants of Immunity: Experimental Basis for Adjuvant Combinations....Pages 449-457 Interrelationship Between Chemotherapy and Immunotherapy in the Treatment of Disseminated Disease....Pages 458-464 Concluding Remarks....Pages 465-465 Back Matter....Pages 467-468 A prospective randomized clinical trial of treatment with vincristine, cyclophosphamide, methotrexate and 5-fluorouracil after conventional curative treatment for stage II breast cancer is described. The results at 2 years are recorded together with details of toxicity. Future plans are discussed briefly. Acknowledgement We wish to acknowledge the participation of all the collaborators in this study, the co-ordinator Dr. ERICA MANSBACHER and the support of Action Cancer in Belfast. References 1. Ahmann, D.L., O'Connell, M.J., Hahn, R.G., Bisel, H.F., Lee, R.A., Edmonson, J.H. : An evaluation of early or delayed adjuvant chemotherapy in premenopause1 patients with advanced breast cancer undergoing oophorectomy. New Engl. J. Med. 297, 356-360 (1977) 2. Ahmann, D.L., Scanlon, P.W., Bisel, H.F., Edmonson, J.H., Frytak, S., Payne, W.S., O'Fallon, J.R., Hahn, R.J., Ingle, J.N., O'Connell, M.J., Rubin, J. : Repeated adjuvant chemotherapy with Phenyl-alanine mustard, or 5-Fluorouracil, Cyclophosphamide and Prednisone with or without radiation after mastectomy for breast cancer. Lancet 1978//, 893-896 3. Bonadonna, G., Rossi, A., Valagussa, P., Banfi, A., Veronesi, U. : The CMF program for operable breast cancer with positive axillary nodes. Cancer 39, 2904-2915 (1977) 4. Edelstyn, G.A., Bates, T.S., Brinkley, D., Macrae, K.D., Spittle, M., Wheeler, T. : Comparison of 5-day, I-day and 2-day cyclical combination chemotherapy in advanced breast cancer